1Biomarkers and Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain.

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

1Cancer Biology and Evolution Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research ...

SELLAS Life Sciences Group announced that its CDK9 inhibitor tambiciclib (SLS009) improved median overall survival (OS) in patients with relapsed or refractory acute myeloid leukemia (AML) in a phase ...

1Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama. 2Division of Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Public health groups and individual scientists together sued the NIH over the discontinuation of hundreds of research grants worth more than $2.4 billion. The lawsuit, filed by NIH-funded scientists ...

Copyright held by the owner/author(s).

*Corresponding Author: Ravi Bhatia, Division of Hematology/Oncology, Department of Medicine, The University of Alabama at Birmingham, 1802 6th Avenue, South, North Pavilion, Room 2555C, Birmingham, AL ...

1Department of Pediatric Oncology, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts. *Corresponding Author: Junne Kamihara, Department of ...

Copyright held by the owner/author(s).